Literature DB >> 17339838

Endothelial dysfunction and compromised eNOS/Akt signaling in the thoracic aorta during the progression of Marfan syndrome.

A W Y Chung1, K Au Yeung, S F Cortes, G G S Sandor, D P Judge, H C Dietz, C van Breemen.   

Abstract

BACKGROUND AND
PURPOSE: Aortic complications account for the major mortality in Marfan syndrome (MFS), a connective tissue disorder caused by mutations in FBN1 encoding fibrillin-1. We hypothesized that MFS impaired endothelial function and nitric oxide (NO) production in the aorta. EXPERIMENTAL APPROACH: Mice (at 3, 6, 9 and 12 months of age) heterozygous for the Fbn1 allele encoding a cysteine substitution (Fbn1 (C1039G/+), Marfan mice, n=75), the most common class of mutation in MFS, were compared with age-matched control littermates (n=75). Thoracic and abdominal aortas from the two groups were studied. KEY
RESULTS: Isometric force measurements revealed that relaxation to ACh (but not to sodium nitroprusside) was diminished in the phenylephrine-precontracted Marfan thoracic aorta at 6 months of age (pEC(50)=6.12+/-0.22; maximal response, E(max)=52.7+/-6.8%; control: pEC(50)=7.34+/-0.19; E(max)=84.8+/-2.2%). At one year, both inhibition of NO production with N(omega)-nitro-L-arginine methyl ester, or denudation of endothelium increased the phenylephrine-stimulated contraction in the control thoracic aorta by 35%, but had no effect in the Marfan aorta, indicating a loss of basal NO production in the Marfan vessel. From 6 months, a reduced phosphorylation of endothelial NOS (eNOS)(Ser1177) and Akt(Thr308) detected by Western blotting was observed in the Marfan thoracic aorta, which was accompanied by decreased levels of cGMP. Expressions of Akt and eNOS in the abdominal aorta were not different between the two groups. CONCLUSIONS AND IMPLICATIONS: MFS impairs endothelial function and signaling of NO production in the thoracic aorta, suggesting the importance of NO in the age-related progression of thoracic aortic manifestations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339838      PMCID: PMC2013910          DOI: 10.1038/sj.bjp.0707181

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

1.  Wall stiffness suppresses Akt/eNOS and cytoprotection in pulse-perfused endothelium.

Authors:  Xinqi Peng; Saptarsi Haldar; Shailesh Deshpande; Kaikobad Irani; David A Kass
Journal:  Hypertension       Date:  2003-02       Impact factor: 10.190

2.  Phenotypic variability of cardiovascular manifestations in Marfan Syndrome. Possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism.

Authors:  Betti Giusti; Maria Cristina Porciani; Tamara Brunelli; Lucia Evangelisti; Sandra Fedi; Gian Franco Gensini; Rosanna Abbate; Guido Sani; Magdi Yacoub; Guglielmina Pepe
Journal:  Eur Heart J       Date:  2003-11       Impact factor: 29.983

3.  Rare manifestation of abdominal aortic aneurysm and popliteal aneurysm in a patient with Marfan's syndrome: a case report.

Authors:  B Wolfgarten; I Krüger; M Gawenda
Journal:  Vasc Surg       Date:  2001 Jan-Feb

4.  Endothelium-dependent vasodilatation in rat aorta is mainly mediated by nitric oxide.

Authors:  C Castillo; G Reyes; B Escalante; P López; E F Castillo
Journal:  Proc West Pharmacol Soc       Date:  1997

5.  Peripheral resistance vessel dysfunction in Marfan syndrome.

Authors:  M Nakamura; S Itoh; S Makita; A Ohira; N Arakawa; K Hiramori
Journal:  Am Heart J       Date:  2000-04       Impact factor: 4.749

6.  Nitric oxide regulates local arterial distensibility in vivo.

Authors:  Ian B Wilkinson; Ahmed Qasem; Carmel M McEniery; David J Webb; Albert P Avolio; John R Cockcroft
Journal:  Circulation       Date:  2002-01-15       Impact factor: 29.690

7.  Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome.

Authors:  Enid R Neptune; Pamela A Frischmeyer; Dan E Arking; Loretha Myers; Tracie E Bunton; Barbara Gayraud; Francesco Ramirez; Lynn Y Sakai; Harry C Dietz
Journal:  Nat Genet       Date:  2003-02-24       Impact factor: 38.330

8.  A novel Doppler echocardiographic method of measuring the biophysical properties of the aorta in pediatric patients.

Authors:  George G S Sandor; Takashi Hishitani; Ross E Petty; Mary T Potts; Astrid Desouza; Eustace Desouza; James E Potts
Journal:  J Am Soc Echocardiogr       Date:  2003-07       Impact factor: 5.251

9.  Pulse pressure and endothelial dysfunction in never-treated hypertensive patients.

Authors:  Roberto Ceravolo; Raffaele Maio; Arturo Pujia; Angela Sciacqua; Giorgio Ventura; Maria C Costa; Giorgio Sesti; Francesco Perticone
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

Review 10.  [Aortic aneurysms excluding Marfan's syndrome].

Authors:  G Jondeau; C Muti; C Boileau
Journal:  Arch Mal Coeur Vaiss       Date:  2003-11
View more
  41 in total

1.  Intrinsic cardiomyopathy in Marfan syndrome: results from in-vivo and ex-vivo studies of the Fbn1C1039G/+ model and longitudinal findings in humans.

Authors:  Laurence Campens; Marjolijn Renard; Bram Trachet; Patrick Segers; Laura Muino Mosquera; Johan De Sutter; Lynn Sakai; Anne De Paepe; Julie De Backer
Journal:  Pediatr Res       Date:  2015-06-04       Impact factor: 3.756

2.  Molecular mechanisms of inherited thoracic aortic disease - from gene variant to surgical aneurysm.

Authors:  Elizabeth Robertson; Candice Dilworth; Yaxin Lu; Brett Hambly; Richmond Jeremy
Journal:  Biophys Rev       Date:  2014-12-06

3.  Sildenafil Prevents Marfan-Associated Emphysema and Early Pulmonary Artery Dilation in Mice.

Authors:  Zoe White; Nadia Milad; Arash Y Tehrani; Jennifer Lamothe; James C Hogg; Mitra Esfandiarei; Michael Seidman; Steven Booth; Tillie-Louise Hackett; Mathieu C Morissette; Pascal Bernatchez
Journal:  Am J Pathol       Date:  2019-05-22       Impact factor: 4.307

Review 4.  Drug-based therapies for vascular disease in Marfan syndrome: from mouse models to human patients.

Authors:  Jason R Cook; Harikiran Nistala; Francesco Ramirez
Journal:  Mt Sinai J Med       Date:  2010 Jul-Aug

5.  Vascular dysfunctions in the isolated aorta of double-transgenic hypertensive mice developing aortic aneurysm.

Authors:  Ludovic Waeckel; Cécile Badier-Commander; Thibaut Damery; Ralf Köhler; Patricia Sansilvestri-Morel; Serge Simonet; Christine Vayssettes-Courchay; Heike Wulff; Michel Félétou
Journal:  Pflugers Arch       Date:  2014-11-12       Impact factor: 3.657

6.  AKT2 confers protection against aortic aneurysms and dissections.

Authors:  Ying H Shen; Lin Zhang; Pingping Ren; Mary T Nguyen; Sili Zou; Darrell Wu; Xing Li Wang; Joseph S Coselli; Scott A LeMaire
Journal:  Circ Res       Date:  2012-12-18       Impact factor: 17.367

7.  Losartan Attenuates Degradation of Aorta and Lung Tissue Micromechanics in a Mouse Model of Severe Marfan Syndrome.

Authors:  Jia-Jye Lee; Josephine Galatioto; Satish Rao; Francesco Ramirez; Kevin D Costa
Journal:  Ann Biomed Eng       Date:  2016-04-18       Impact factor: 3.934

8.  Dysfunction of endothelial and smooth muscle cells in small arteries of a mouse model of Marfan syndrome.

Authors:  H T Syyong; A W Y Chung; H H C Yang; C van Breemen
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

9.  Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome.

Authors:  H H Clarice Yang; Jong Moo Kim; Elliott Chum; Cornelis van Breemen; Ada W Y Chung
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

10.  Indomethacin Prevents the Progression of Thoracic Aortic Aneurysm in Marfan Syndrome Mice.

Authors:  Gao Guo; Claus-Eric Ott; Johannes Grünhagen; Begoña Muñoz-García; Angelika Pletschacher; Klaus Kallenbach; Yskert von Kodolitsch; Peter N Robinson
Journal:  Aorta (Stamford)       Date:  2013-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.